Pharmaceuticals, Biotechnology and Life Sciences
NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES NEWS WIRE SERVICES HALIFAX, Nova Scotia–(BUSINESS WIRE)–$IMV #AntibioticDeveloper–Biopharmaceutical company…
Veeva delivers a modern cloud application for the management of adverse events PLEASANTON, Calif.–(BUSINESS WIRE)–#drugsafety—Veeva Systems (NYSE:VEEV) today announced the…
Additional Data Points to Potential of XERAVA to Treat Carbapenem-Resistant, Multidrug-Resistant Escherichia Coli TP-6076 Demonstrates In Vivo Efficacy…
Social media and news aggregation site will highlight real-time digital conversations at DIA 2019 DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a…
PRINCETON, N.J.–(BUSINESS WIRE)–$BMY—Bristol-Myers Squibb Company (NYSE:BMY) today announced topline results from CheckMate -459, a randomized Phase 3 study evaluating Opdivo…
Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute GvHD with no safety concerns occurring within the study—
Vladislav Sandler, Chief Executive Officer of Hemogenyx Pharmaceuticals, said the potential of the ApbHC, a new generation of our humanized mice, which has allowed the company to rapidly obtain in vivo data on the efficacy of the company’s CDX antibodies against AML.
Evgen Pharma’s lead product, SFX-01, has been featured in a recently published paper, in the journal “Oxidative Medicine and Cellular Longevity”, describing Phase IIb trial in subarachnoid haemorrhage (“SAH”) at University Hospital Southampton.
Vertex’s third medicine approved to treat the underlying cause of CF in eligible patients in this age range-
EMMAC, the European independent medical cannabis company, is pleased to announce an exclusive collaboration with Hyris Ltd, a UK-based biotechnology company, to develop a comprehensive library of genetic profiles of existing cannabis varieties, and to industrialise DNA-based methods for the identification of its unique branded cultivars.